Challenges in antibody–drug conjugate discovery: a bioconjugation and analytical perspective

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985

(2015) Ronald C. Elgersma et al.   MOLECULAR PHARMACEUTICS

A CXCR4-Targeted Site-Specific Antibody-Drug Conjugate

(2014) Sumith A. Kularatne et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials

(2014) X. Li et al.   ANNALS OF ONCOLOGY

Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study

(2014) Michelle A. Fanale et al.   JOURNAL OF CLINICAL ONCOLOGY

Analytical and bioanalytical technologies for characterizing antibody–drug conjugates

(2013) Stephen C Alley et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics

(2013) Surinder Kaur et al.   Bioanalysis

Analytical methods for physicochemical characterization of antibody drug conjugates

(2011) Aditya Wakankar et al.   mAbs

Challenges in developing bioanalytical assays for characterization of antibody–drug conjugates

(2011) Jean Philippe Stephan et al.   Bioanalysis

Cell-based assays: fuelling drug discovery

(2010) Elisa Michelini et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

(2010) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

(2009) Laurent Ducry et al.   BIOCONJUGATE CHEMISTRY

Potent antibody drug conjugates for cancer therapy

(2009) Peter D Senter   CURRENT OPINION IN CHEMICAL BIOLOGY